United States - English - NLM (National Library of Medicine)

bi-coastal pharma international llc - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5), sulfur (unii: 70fd1kfu70) (sulfur - unii:70fd1kfu70) - sulfacetamide sodium and sulfur cleanser is indicated in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis. sulfacetamide sodium and sulfur cleanser is contraindicated for use by patients having known hypersensitivity to sulfonamides, sulfur or any other component of this preparation. sulfacetamide sodium and sulfur cleanser is not to be used by patients with kidney disease.

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5), prednisolone sodium phosphate (unii: iv021nxa9j) (prednisolone - unii:9phq9y1olm) - sulfacetamide sodium and prednisolone sodium phosphate ophthalmic solution is indicated for corticosteroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain diminution in edema and inflammation. they are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation, or thermal burns or penetration of foreign bodies. the use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. the particular anti-infective drug in this product is active

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5) - sulfacetamide sodium ophthalmic solution usp, 10% is indicated for the treatment of conjunctivitis and other superficial ocular infections due to susceptible microorganisms, and as an adjunctive in systemic sulfonamide therapy of trachoma: escherichia coli, staphylococcus aureus, streptococcus pneumoniae, streptococcus  (viridans group), haemophilus influenzae, klebsiella  species, and enterobacter  species. topically applied sulfonamides do not provide adequate coverage against neisseria  species, serratia marcescens  and pseudomonas aeruginosa . a significant percentage of staphylococcal isolates are completely resistant to sulfa drugs. sulfacetamide sodium ophthalmic solution usp, 10% is contraindicated in individuals who have a hypersensitivity to sulfonamides or to any ingredient of the preparation.

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5) - sulfacetamide sodium ophthalmic solution, usp 10% is indicated for the treatment of conjunctivitis and other superficial ocular infections due to susceptible microorganisms, and as an adjunctive in systemic sulfonamide therapy of trachoma: escherichia coli, staphylococcus aureus, streptococcus pneumoniae, streptococcus (viridans group), haemophilus influenzae, klebsiella species, and enterobacter species. topically applied sulfonamides do not provide adequate coverage against neisseria species, serratia marcescens and pseudomonas aeruginosa . a significant percentage of staphylococcal isolates are completely resistant to sulfa drugs. sulfacetamide sodium ophthalmic solution, usp 10% is contraindicated in individuals who have a hypersensitivity to sulfonamides or to any ingredient of the preparation.

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5), prednisolone sodium phosphate (unii: iv021nxa9j) (prednisolone - unii:9phq9y1olm) - sulfacetamide sodium and prednisolone sodium phosphate ophthalmic solution is indicated for corticosteroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain diminution in edema and inflammation. they are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation, or thermal burns or penetration of foreign bodies. the use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. the particular anti-infective drug in this product is active

United States - English - NLM (National Library of Medicine)

asclemed usa, inc. - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5) - sulfacetamide sodium ophthalmic solution, usp 10% is indicated for the treatment of conjunctivitis and other superficial ocular infections due to susceptible microorganisms, and as an adjunctive in systemic sulfonamide therapy of trachoma: escherichia coli, staphylococcus aureus, streptococcus pneumoniae, streptococcus (viridans group), haemophilus influenzae, klebsiella species, and enterobacter species. topically applied sulfonamides do not provide adequate coverage against neisseria species, serratia marcescens and pseudomonas aeruginosa . a significant percentage of staphylococcal isolates are completely resistant to sulfa drugs. sulfacetamide sodium ophthalmic solution, usp 10% is contraindicated in individuals who have a hypersensitivity to sulfonamides or to any ingredient of the preparation.

United States - English - NLM (National Library of Medicine)

proficient rx lp - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5) - sulfacetamide sodium ophthalmic solution, usp 10% is indicated for the treatment of conjunctivitis and other superficial ocular infections due to susceptible microorganisms, and as an adjunctive in systemic sulfonamide therapy of trachoma: escherichia coli, staphylococcus aureus, streptococcus pneumoniae, streptococcus (viridans group), haemophilus influenzae, klebsiella species, and enterobacter species. topically applied sulfonamides do not provide adequate coverage against neisseria species, serratia marcescens and pseudomonas aeruginosa . a significant percentage of staphylococcal isolates are completely resistant to sulfa drugs. sulfacetamide sodium ophthalmic solution, usp 10% is contraindicated in individuals who have a hypersensitivity to sulfonamides or to any ingredient of the preparation.

United States - English - NLM (National Library of Medicine)

medimetriks pharmaceuticals, inc. - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5), sulfur (unii: 70fd1kfu70) (sulfur - unii:70fd1kfu70) - sulfacetamide sodium 100 mg in 1 g - sumaxin® (sodium sulfacetamide 10% & sulfur 4%) cleansing pads are indicated in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis. sumaxin® (sodium sulfacetamide 10% & sulfur 4%) cleansing pads are contraindicated for use by patients having known hypersensitivity to sulfonamides, sulfur or any other component of this preparation. sumaxin® (sodium sulfacetamide 10% & sulfur 4%) cleansing pads are not to be used by patients with kidney disease.

United States - English - NLM (National Library of Medicine)

biocomp pharma, inc. - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5) - sulfacetamide sodium 100 mg in 1 ml - this product is intended for topical application in the following scaling dermatoses: seborrheic dermatitis and seborrhea sicca (dandruff). it also is indicated for the treatment of secondary bacterial infections of the skin due to organisms susceptible to sulfonamides. this product is contraindicated in persons with known or suspected hypersensitivity to any of the ingredients of the product. this product is not to be used by patients with kidney disease. general: nonsusceptible organisms, including fungi, may proliferate with the use of this preparation. although rare, sensitivity to sodium sulfacetamide may occur. therefore, caution and careful supervision should be observed when prescribing this drug for patients who may be prone to hypersensitivity to topical sulfonamides. if the use of this product produces signs of hypersensitivity or other untoward reactions, discontinue use of the preparation. patients should be carefully observed for possible local irritation or sensitization during long-term therapy. systemic toxic reactions such as agranulocytosis, acute hemolytic anemia, purpura hemorrhagica, drug fever, jaundice and contact dermatitis indicate hypersensitivity to sulfonamides. particular caution should be employed if areas of denuded or abraded skin are involved. systemic absorption of topical sulfonamides is greater following application to large, infected, abraded, denuded or severely burned areas. under these circumstances, any of the adverse effects produced by the systemic administration of these agents could potentially occur, and appropriate observations and laboratory determinations should be performed. information for patients: patients should discontinue the use of this product if the condition becomes worse or if a rash develops in the area being treated or elsewhere. the use of this product also should be discontinued promptly and the physician notified if any arthritis, fever or sores in the mouth develop. avoid contact with eyes, lips and mucous membranes. drug interactions: this product is incompatible with silver preparations. carcinogenesis, mutagenesis and impairment of fertility: long-term animal studies for carcinogenic potential have not been performed on this product to date. studies on reproduction and fertility also have not been performed. chromosomal nondisjunction has been reported in the yeast, saccharomyces cerevisiae, following application of sodium sulfacetamide. the significance of this finding to the topical use of sodium sulfacetamide in the human is unknown. pregnancy: category c. animal reproduction studies have not been conducted with this product. it is also not known whether this product can affect reproduction capacity or cause fetal harm when administered to a pregnant woman. this product should be used by a pregnant woman only if clearly needed or when potential benefits outweigh potential hazards to the fetus. nursing mothers: it is not known whether this drug is excreted in human milk. because many drugs are excreted in human milk, caution should be exercised when this product is administered to a nursing woman. pediatric use: safety and effectiveness in children under the age of 12 years have not been established.

United States - English - NLM (National Library of Medicine)

exact-rx, inc. - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5) - sulfacetamide sodium 100 mg in 1 ml - indications : sodium sulfacetemide 10% wash is intended for topical application in the following scaling dermatoses: seborrheic dermatisis and seborrhea sicca (dandruff). it also is indicated for the treatment of secondary bacterial infections of the skin due to organisms susceptible to sulfonamides. contraindications: sodium sulfacetamide 10% wash is contraindicated in persons with know or suspected hypersensitivity to sulfonamides.